Novo Nordisk CFO describes roller-coaster growth and stays optimistic about CagriSema after Q2 earnings
Novo Nordisk CFO Karsten Munk Knudsen talked to Fierce after the company released its second-quarter earnings, reflecting on his nine-year tenure and the firm’s volatile performance.
He recalled an early period of modest growth and pressure, followed by a phase of rapid expansion where quarterly growth rates reached 20-40% and the company had to scale manufacturing to meet demand.
That momentum faded quickly, leading to slower growth, investor disappointment and a notable drop in the share price over the past two quarters.
Despite the setbacks, Knudsen said he remains confident in the upcoming obesity drug CagriSema and the longer-term outlook for Novo Nordisk.
This writeup was produced by pharmadog from original reporting by Fierce Biotech.
Original headline: “‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth”
read at Fierce Biotech ↗
comments(0)
5-min edit window · permanent after that